Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, randomized, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral haemorrhage

Next Previous
Trial Profile

A phase III, randomized, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral haemorrhage

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alteplase (Primary)
  • Indications Intracranial haemorrhages
  • Focus Therapeutic Use
  • Acronyms MISTIE III

    • Most Recent Events

    • 22 Apr 2021 Results of pooled analysis from ATACH-2 and MISTIE III assessing the relationship between the presence of cerebral microbleeds and acute hematoma characteristics among patients with intracerebral hemorrhage, presented at the 73rd Annual Meeting of the American Academy of Neurology.
    • 19 Mar 2021 Results of secondary analysis from Mistie III Trial presented at the International Stroke Conference 2021
    • 20 Jan 2021 Results of pooled analysis from MISTIE III and ATACH-2 assessing the that presence of a DWI lesion is associated with a higher risk of stroke among ICH survivors, and sought to study this relationship using prospective data from 2 ICH cohorts,published in the Stroke
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top